[
  {
    "ts": null,
    "headline": "Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.",
    "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV",
    "url": "https://finnhub.io/api/news?id=b30b8ea5e43fcd4c82fa72dc8bed3659bb4a126cbfeebb022995122fb62bf432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759788300,
      "headline": "Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.",
      "id": 136999662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV",
      "url": "https://finnhub.io/api/news?id=b30b8ea5e43fcd4c82fa72dc8bed3659bb4a126cbfeebb022995122fb62bf432"
    }
  },
  {
    "ts": null,
    "headline": "Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD",
    "url": "https://finnhub.io/api/news?id=e446d768e4625d9ba67789ef5e3d699733603f9e0aaf0eed4d6cfd6b4af1e0fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759782600,
      "headline": "Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease",
      "id": 136999663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD",
      "url": "https://finnhub.io/api/news?id=e446d768e4625d9ba67789ef5e3d699733603f9e0aaf0eed4d6cfd6b4af1e0fa"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=62281b3832860e3e28d8abf041f122dc3c7d93be04ea14e14101c1b4ec52c696",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759768200,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 137025363,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=62281b3832860e3e28d8abf041f122dc3c7d93be04ea14e14101c1b4ec52c696"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  }
]